FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, particularly to producing a population of MAFA expressing cells. Method involves differentiation of human cells expressing markers characteristic for line of formed endoderm, obtained from pluripotent stem cells, which are human pluripotent stem cells obtained without destruction of human embryo, human pluripotent stem cells of non-embryonic origin, cells from the human embryonic stem cell line H1, cells from a human embryonic stem cell line H7, cells from a human embryonic stem cell line H9, or cells from a human embryonic stem cell line SA002, into human cells expressing markers characteristic of the pancreatic endoderm line. That is followed by differentiating human cells expressing markers characteristic of a pancreatic endoderm line into human cells expressing markers characteristic of a line of pancreatic endocrine cells expressing at least one of NGN3, NEUROD, ISL1, PDX1, NKX6.1, PAX4 and PTF1-alpha; and treating human cells expressing markers specific to the pancreatic endocrine cell line, with a kinase inhibitor selected from the group consisting of 2-cyanoethyl alster-paullonom; SU9516; alster-pumpallon; Cdk1/2-inhibitor III; casein kinase I inhibitor; Akt-inhibitor IV; EGFR-inhibitor; MEK1/2-inhibitor; staurosporine N-benzoyl-, PKR-inhibitor and PDGF receptor IV tyrosine kinase inhibitor.
EFFECT: invention widens the range of agents.
21 cl, 16 dwg, 7 tbl, 9 ex
